Genesis IBRC India Ltd

Genesis IBRC India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 Jan 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 13 March 2026, providing investors with an up-to-date analysis of the company’s standing.

Genesis IBRC India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 March 2026, providing investors with the latest insights into its performance and outlook.

Genesis IBRC India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Genesis IBRC India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 January 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 08 February 2026, providing investors with the latest comprehensive analysis.

Genesis IBRC India Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 27 Jan 2026, reflecting a nuanced shift in its financial and market outlook. Despite persistent challenges in profitability and valuation, certain technical and financial trend parameters have shown stabilisation, prompting a reassessment of the company’s investment appeal within the Pharmaceuticals & Biotechnology sector.

Genesis IBRC India Ltd has been downgraded from a Sell to a Strong Sell rating as of 20 Jan 2026, reflecting deteriorating technical indicators and valuation concerns despite its impressive long-term returns. The downgrade follows a comprehensive reassessment across four key parameters: Quality, Valuation, Financial Trend, and Technicals, signalling caution for investors amid flat recent financial performance and mixed market signals.

Genesis IBRC India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Genesis IBRC India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with an up-to-date perspective on the company's performance and outlook.

Genesis IBRC India Ltd has encountered significant selling pressure, with the stock registering a sharp decline of 5.0% today and exhibiting a persistent downward trend over the past 18 trading sessions. The absence of buyers and the presence of only sell orders have intensified concerns about distress selling within the Pharmaceuticals & Biotechnology sector.

Genesis IBRC, a microcap player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its market evaluation metrics, reflecting a nuanced shift in its financial and technical outlook. This adjustment comes amid a backdrop of volatile stock returns and a complex fundamental profile.

Genesis IBRC India Ltd has encountered severe selling pressure on 4 Dec 2025, with the stock hitting the lower circuit and registering exclusively sell orders. This distress selling signals a critical phase for the pharmaceutical and biotechnology company as it experiences consecutive losses and a sharp decline in market sentiment.

Genesis IBRC India Ltd has encountered significant selling pressure, with the stock registering a sharp decline of 4.97% today and exhibiting a persistent downtrend over the past sixteen trading sessions. The absence of buyers and continuous sell orders have resulted in a distressing market scenario for this Pharmaceuticals & Biotechnology company.

Genesis IBRC India Ltd is currently experiencing severe selling pressure, with the stock locked in a lower circuit and an absence of buyers on the order book. This situation signals distress selling and highlights a challenging phase for the pharmaceutical and biotechnology company amid a series of consecutive losses over recent weeks.

Genesis IBRC India has encountered significant selling pressure, with the stock registering a day marked exclusively by sell orders. This extreme market behaviour signals distress selling, as the company’s shares continue to face downward momentum following a prolonged period of consecutive losses.

Genesis IBRC India is currently experiencing significant selling pressure, with the stock locked at its lower circuit and an absence of buyers in the market. This distress selling has resulted in a continuous decline over the past 13 trading sessions, signalling a challenging phase for the pharmaceutical and biotechnology company.

Genesis IBRC India Ltd is currently experiencing significant selling pressure, with the stock locked in a lower circuit and an absence of buyers on the order book. This distress selling has resulted in a continuous decline over the past 12 trading sessions, signalling heightened investor caution in the Pharmaceuticals & Biotechnology sector.

Genesis IBRC India Ltd is currently experiencing a pronounced selling wave, with the stock locked at its lower circuit and an absence of buyers in the queue. This extreme selling pressure has resulted in an uninterrupted decline over the past 11 trading sessions, signalling distress among investors in the Pharmaceuticals & Biotechnology sector.

Genesis IBRC India has encountered significant selling pressure in the latest trading session, with the stock registering a decline of 2.00% while the Sensex showed a marginal gain of 0.06%. The absence of buyers and a queue dominated solely by sell orders signal distress selling, marking a notable shift in market sentiment for the pharmaceutical and biotechnology company.